You are here: Industry Insights > NICE

News List

NICE recommends Novartis' Extavia for MS, but knocks back a raft of other beta interferons pharmafile
December 21, 2017
NICE has revealed that it has passed draft guidance that recommends Novartis’ Extavia for the treatment of relapsing- remittingMS or secondary progressive MS with continued relapses in adult patients, provided on the NHS in England and Wales.
NICE nods for AbbVie in hep C and Novartis in lung cancer pharmatimes
December 11, 2017
NICE has published new draft guidance for Novartis' Zykadia and AbbVie's Maviret.
NICE issues new recommendations for asthma care biospectrumasia
December 04, 2017
The recommended objective tests include spirometry and FeNO.
Bayer’s Stivarga wins NICE approval for GIST pharmatimes
November 21, 2017
Bayer’s Stivarga has been recommended by the National Institute for Health and Care Excellence as a treatment for some patients with gastrointestinal stromal tumours (GIST).
NICE recommends Kisqali as a cost-effective treatment for advanced breast cancer europeanpharmaceuticalreview
November 17, 2017
NICE recommends Kisqali as a cost-effective treatment option for postmenopausal women within England and Wales with advanced breast cancer…
NICE approves Novartis and Pfizer’s rival breast cancer drugs pharmafile
November 17, 2017
NICE has announced that it has given the nod to two new treatments for breast cancer with the approval of Pfizer’s Ibrance (palbociclib) and Novartis’ Kisqali (ribociclib).
NICE backs Merck’s Mavenclad for MS pharmatimes
November 13, 2017
Merck’s Mavenclad is being backed by the National Institute for Health and Clinical Excellence as an option for treating highly active multiple sclerosis in adults on the NHS.
NICE shoots down Bayer's Stivarga in liver cancer, citing price, clinical questions fiercepharma
November 09, 2017
Bayer is working to position Stivarga as part of a treatment regimen for those who have failed on its first-line liver cancer fighter, Nexavar. But that’s not going to work in England. At least, not yet.
Bayer’s Stivarga rejected by NICE for liver cancer pharmatimes
November 09, 2017
Bayer’s Stivarga is not being recommended by NHS treatment cost regulators for certain patients with advanced unresectable hepatocellular carcinoma.
Final NICE nod for Sanofi’s Kevzara pharmatimes
November 03, 2017
The National Institute for Health and Care Excellence has issued final guidance backing Sanofi’s Kevzara as a new treatment option for adults with severe, active rheumatoid arthritis (RA).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page